Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism.
Saved in:
| Title: | Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism. |
|---|---|
| Authors: | Vaquié AM; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Shah DR; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Brechbühl EES; Cancer Research-UK, Cambridge Research Institute, University of Cambridge, UK., McNicholas M; Department of Oncology, Early Cancer Institute, University of Cambridge, UK.; Cancer Research-UK, Children's Brain Tumour Centre of Excellence, University of Cambridge, UK., Xu Z; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Stockley JH; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Morcom L; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Gold Diaz D; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Girdler GC; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Seear RV; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, UK., Balmus G; Department of Clinical Neuroscience, UK Dementia Research Institute, University of Cambridge, UK.; Department of Molecular Neuroscience, Transylvanian Institute of Neuroscience, Cluj-Napoca, Romania., Ratan RR; Burke Neurological Institute and Brain and Mind Research Institute, Weill Cornell Medicine, White Plains, NY, USA., Bulstrode H; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK., Nathan JA; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, UK., Pathania M; Department of Oncology, Early Cancer Institute, University of Cambridge, UK.; Cancer Research-UK, Children's Brain Tumour Centre of Excellence, University of Cambridge, UK., Brindle KM; Cancer Research-UK, Cambridge Research Institute, University of Cambridge, UK., Rowitch DH; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.; Departments of Pediatrics and Neurosurgery, Cedars-Sinai Guerin Children's, Los Angeles, CA, USA. |
| Source: | Molecular oncology [Mol Oncol] 2026 Feb; Vol. 20 (2), pp. 307-330. Date of Electronic Publication: 2025 Sep 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.70128 |
